TOPLINE:
Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.
METHODOLOGY:
- Researchers conducted a longitudinal retrospective analysis to investigate whether the serum IFN score could predict clinically meaningful progression in patients with lcSSc using a novel composite endpoint calculated using serum biomarkers.
- Overall, 149 patients with lcSSc (mean age, 60 years; 96% women; median disease duration, 8 years) were recruited between December 2013 and November 2019 from a single center in the United Kingdom and followed up for a median duration of 88 months.
- The IFN score was calculated on the basis of the serum concentration of six…